[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Observation
June 2013

Progranulin Mutations as Risk Factors for Alzheimer Disease

Author Affiliations

Author Affiliations: Department of Neurology, University of California, San Francisco (Drs Perry, Lehmann, Yokoyama, Grinberg, Seeley, Miller, Rosen, and Rabinovici, and Ms Karydas); and Departments of Psychiatry and Neurology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (Mr Lee and Drs Coppola and Geschwind).

JAMA Neurol. 2013;70(6):774-778. doi:10.1001/2013.jamaneurol.393
Abstract

Importance Mutations in the progranulin gene are known to cause diverse clinical syndromes, all attributed to frontotemporal lobar degeneration. We describe 2 patients with progranulin gene mutations and evidence of Alzheimer disease (AD) pathology. We also conducted a literature review.

Observations This study focused on case reports of 2 unrelated patients with progranulin mutations at the University of California, San Francisco, Memory and Aging Center. One patient presented at age 65 years with a clinical syndrome suggestive of AD and showed evidence of amyloid aggregation on positron emission tomography. Another patient presented at age 54 years with logopenic progressive aphasia and, at autopsy, showed both frontotemporal lobar degeneration with TDP-43 inclusions and AD.

Conclusions and Relevance In addition to autosomal-dominant frontotemporal lobar degeneration, mutations in the progranulin gene may be a risk factor for AD clinical phenotypes and neuropathology.

One of the challenges facing clinicians who evaluate patients with dementia is determining what clinical syndrome best fits with the patient's presentation and then predicting the most likely underlying molecular pathology. While clinical syndromes often help with this prediction, there is still variability between syndrome and pathology. The term frontotemporal dementia (FTD) refers to a heterogeneous group of clinical syndromes featuring changes in personality, behavior, or language. Frontotemporal lobar degeneration (FTLD) refers to a collection of pathologic diagnoses that can cause these clinical syndromes. Three major genes have been implicated in autosomal-dominant FTD: microtubule associated protein tau (MAPT), progranulin (GRN), and chromosome 9 open reading frame 72 (C9orf72). While mutations in GRN have been described as causing a variety of clinical syndromes, including one suggesting Alzheimer disease (AD), it is thought these various presentations all result from TAR DNA-binding protein 43 (TDP-43) pathology. Here we present 2 patients who suggest GRN mutations may also be risk factors for AD pathology.

REPORT OF CASES
CASE 1

A 65-year-old right-handed man presented with 3 years of slowly progressive cognitive changes. His first symptom was misplacing personal items. He retired and attempted to move his office into his home but ultimately left everything packed in boxes on the floor. Subsequently, he had several minor motor vehicle accidents and exhibited poor financial judgment, borrowing up to $150 000 and forgetting to file his taxes. His memory for recent events became impaired, and he developed word-finding difficulties. He angered more easily and compulsively checked door locks. There was no behavioral disinhibition, apathy, loss of empathy, or change in food preferences.

On examination, he asked repetitive questions, was suspicious of the examiner, and made phonemic paraphasic errors in speech. He had mild bilateral agraphesthesia. He scored 17 of 30 on the Mini-Mental State Examination.1 Detailed neuropsychologic testing revealed poor verbal and visual memory, confrontational naming, and executive function with relative preservation of visuospatial skills (Table).

Table. Neuropsychological Testing
Table. Neuropsychological Testing
Table. Neuropsychological Testing

Voxel-based morphometry2 was performed on the patient's 3-T magnetic resonance imaging scan using SPM version 8 (http://www.fil.ion.ucl.ac.uk/spm/). Preprocessing included segmentation into gray and white matter, alignment and warping with DARTEL,3 normalization to Montreal Neurological Institute space, modulation, and smoothing with an 8-mm full-width at half maximum Gaussian kernel. Single-subject voxel-based morphometry of combined gray and white matter segmentations was compared with 30 healthy control subjects matched for sex, age, and scanner. Age and total intracranial volume were included as covariates in the regression. Results, displayed in Figure 1A at a threshold of P < .05 (uncorrected), showed atrophy of medial and lateral temporal and parietal lobes, right greater than left. Based on his clinical presentation, neuropsychologic testing, and imaging, he was diagnosed as having AD.

Figure 1. Voxel-based morphometry. Single-subject voxel-based morphometry of case 1 (A) and case 2 (B), uncorrected for multiple comparisons at P < .05, displayed as T map (1 < t < 4) and overlaid on Montreal Neurological Institute template brain. Images are displayed in neurological convention.

Figure 1. Voxel-based morphometry. Single-subject voxel-based morphometry of case 1 (A) and case 2 (B), uncorrected for multiple comparisons at P < .05, displayed as T map (1 < t < 4) and overlaid on Montreal Neurological Institute template brain. Images are displayed in neurological convention.

Positron emission tomography (PET) with the β-amyloid (Aβ) tracer Pittsburgh Compound B was positive for cortical tracer binding, and PET with fluorodeoxyglucose showed hypometabolism in the bilateral temporoparietal cortex (Figure 2).

Figure 2. Positron emission tomography (PET) imaging of case 1. The PET with fluorodeoxyglucose (FDG) shows bilateral temporoparietal hypometabolism and the Pittsburgh compound B (PiB)–PET image of case 1 shows amyloid tracer binding. DVR indicates distribution volume ratio; SUVR, standardized uptake value ratio.

Figure 2. Positron emission tomography (PET) imaging of case 1. The PET with fluorodeoxyglucose (FDG) shows bilateral temporoparietal hypometabolism and the Pittsburgh compound B (PiB)–PET image of case 1 shows amyloid tracer binding. DVR indicates distribution volume ratio; SUVR, standardized uptake value ratio.

The patient had a family history of FTD in 3 maternal relatives. His father had late-life dementia and paternal grandmother had been diagnosed as having AD. Genetic testing revealed that the patient carried the same novel mutation in GRN as his affected maternal family members, an octanucleotide insertion in the coding region (c.1263_1264insGAAGCGAG) causing frameshift and a premature stop codon, predicted to result in nonsense-mediated messenger RNA decay. His apolipoprotein E (APOE) genotype was ϵ3/ϵ4.

CASE 2

A 54-year-old woman presented for evaluation owing to 1 year of progressive language impairment involving difficulties with word finding, remembering names, and expressing herself. Her family said her speech was occasionally nonsensical, describing it “like a word salad.” Within a few months, she developed difficulty writing and spelling, as well as decreased speech output. There were no reported problems with recognizing words. Memory complaints were minimal and, other than anxiety, there was no change in personality or behavior. She had some difficulty with navigation but did not get lost, and there were no motor symptoms.

Her examination was notable for long word-finding pauses and sparse speech, mostly consisting of single words and short phrases. There were no articulation problems. She could follow simple commands but had difficulty with complex instructions. She scored 14 of 30 on the Mini-Mental State Examination. On neuropsychologic testing, she displayed poor verbal memory (that benefitted from recognition), impairment in working memory and executive functions, and language impairment including impairment in repetition, comprehension of syntactically complex sentences, confrontational naming (that benefitted from multiple choice), and verbal fluency (Table).

Voxel-based morphometry was performed on her 1.5-T magnetic resonance imaging (preprocessing and analysis, as in case 1) and was compared against 16 control subjects matched as previously described (Figure 1B). There was asymmetric atrophy involving the left temporal lobe, left medial and inferior frontal regions, and left inferior parietal lobe.

She had a family history of dementia, including a father who died mute at age 65 years and a paternal grandmother and brother who had been diagnosed as having FTD. Her genetic testing revealed a novel GRN mutation, affecting the first protein residue (g.1A>T, p.M1?). Other distinct pathogenic mutations of the same residue have been reported (g.1A>G, p.M1?4; g.2T>C, p.M1?5,6; and g.3G>A, p.M1?7). Her APOE genotype was ϵ3/ϵ4.

The patient died at age 55 years, and an autopsy was performed 8 days post mortem. The entire brain showed advanced autolysis, which precluded meaningful observations about cerebral atrophy and limited immunohistochemical analysis. Nonetheless, immunohistochemistry for Aβ (3FR antibody, antimouse, 1:250; Millipore), hyperphosphorylated tau (PHF-1 antibody, antimouse, 1:250, courtesy of Peter Davies, PhD, Albert Einstein College of Medicine), and TDP-43 (antirabbit, 1:2000; Proteintech Group) was performed on a subset of regions showing relative tissue integrity, including medial temporal lobe, middle frontal gyrus, precentral and postcentral gyri, angular gyrus, superior temporal gyrus, and lateral occipital cortex. These analyses revealed moderate to frequent neuritic amyloid plaques (Figure 3A) in all regions examined, and moderate to frequent tau-positive neurofibrillary tangles in medial temporal and neocortical regions (Figure 3B) but not the primary sensorimotor cortex, consistent with National Institute on Aging–Reagan criteria for high-likelihood AD8 and a Braak AD stage of V.9 In addition, we observed superficial greater than deep laminar TDP-43 pathology consisting of moderate to frequent small round or crescentic neuronal cytoplasmic inclusions and neuropil threads (Figure 3C) accompanied by scarce neuronal nuclear inclusions and glial cytoplasmic inclusions (not pictured), consistent with FTLD-TDP, harmonized type A,10 the subtype seen in GRN mutation carriers.

Figure 3. Pathologic findings for case 2. In the angular gyrus, frequent β-amyloid–positive neuritic plaques (3F4 antibody, hematoxylin counterstain) (A) and sparse to moderate neurofibrillary tangles and neuropil threads are seen (PHF-1 antibody, hematoxylin counterstain) (B). C, Dorsolateral frontal cortex shows frequent TAR DNA-binding protein 43 (TDP-43)–immunoreactive crescentic or compact neuronal cytoplasmic inclusions with surrounding wispy neuropil threads, consistent with frontotemporal lobar degeneration–TDP, type A. Scale bars indicated 500 μM (A), 100 μM (B), and 50 μM (C).

Figure 3. Pathologic findings for case 2. In the angular gyrus, frequent β-amyloid–positive neuritic plaques (3F4 antibody, hematoxylin counterstain) (A) and sparse to moderate neurofibrillary tangles and neuropil threads are seen (PHF-1 antibody, hematoxylin counterstain) (B). C, Dorsolateral frontal cortex shows frequent TAR DNA-binding protein 43 (TDP-43)–immunoreactive crescentic or compact neuronal cytoplasmic inclusions with surrounding wispy neuropil threads, consistent with frontotemporal lobar degeneration–TDP, type A. Scale bars indicated 500 μM (A), 100 μM (B), and 50 μM (C).

DISCUSSION

We present 2 patients with a clinical presentation consistent with AD, one an amnestic type and the other suggestive of logopenic progressive aphasia, a syndrome typically caused by AD pathology.11 One patient had a positive amyloid PET scan demonstrating fibrillary amyloid pathology suggestive of AD and the other had autopsy confirmation of AD pathology. Notably, both patients harbored a GRN mutation, which predicts underlying FTLD-TDP pathology rather than AD.

Mutations in GRN have been associated with several clinical syndromes, including behavioral-variant FTD (bvFTD), nonfluent primary progressive aphasia, and corticobasal syndrome.4 Prior studies have also noted that 9% to 17% of GRN mutation carriers may present with an AD phenotype.4,12 While pathologic validation is lacking in most cases, one such patient had both AD and FTLD-TDP at autopsy13 and another showed an AD-like cerebrospinal fluid biomarker profile with an AD-like syndrome (low Aβ42 and elevated total tau).14 Other studies have indicated that polymorphisms in GRN modify the risk for developing AD.1517 As prior clinicopathological series of GRN have shown only rare evidence of copathology with AD,12,13 if there is a risk for AD conferred by alterations in GRN, the association is less direct than with FTLD.

Prior data on the influence of APOE status on clinical phenotype in GRN carriers has been mixed, with one study showing early memory problems in ϵ4 allele carriers,12 and 2 other studies showing no clear modulatory effect on clinical symptoms.5,18 Both patients in this report were heterozygous for the APOE ϵ4 allele. It is possible that AD pathology found in these patients was strictly due to APOE ϵ4 status, as the prevalence of amyloid deposition (as detected by Pittsburgh Compound B–PET imaging) is approximately 10% in 45-year-old to 59-year-old cognitively normal ϵ4 carriers, and 37% in 60-year-old to 69-year-old carriers.19 On the other hand, the early age at symptom onset and the AD-like clinical syndrome and atrophy pattern, as well as the advanced neurofibrillary pathology (Braak stage V), seen in case 2 argue that AD contributed to and perhaps was the main cause of dementia.

Mutations in GRN are thought to lead to neurodegeneration via haploinsufficiency, although the direct molecular link to TDP-43 translocation and aggregation remains unclear. Recent theories have focused on the anti-inflammatory properties of the progranulin protein.20 Mutations in GRN result in haploinsufficiency of functional progranulin, which might then result in a proinflammatory state. Patients with GRN mutations have been shown to have elevated levels of the proinflammatory cytokine interleukin 6.21 Functional progranulin promotes an increase in the anti-inflammatory cytokine interleukin 10 in macrophages,22 which would be decreased in haploinsufficiency. Progranulin interacts with tumor necrosis factor (TNF) receptors, thereby antagonizing TNF-α activity.23 Therefore, in a state of progranulin deficiency, relative TNF-α activity is increased.

This proinflammatory state might predispose not only to the development of FTLD, but to other forms of neurodegeneration. Alzheimer disease has also been linked to increased expression of inflammatory cytokines,24 and microglial activation has been observed in AD post mortem25 and in vivo.26 Whether this activity is detrimental or protective and primary or secondary has been debated, but there is evidence suggesting that high levels of proinflammatory cytokines might decrease phagocytosis of Aβ by microglia.27 An increase in TNF-α is associated with cognitive decline in AD.28 In mouse models of AD, TNF-α is implicated in enhanced amyloid production,29 tau hyperphosphorylation, and cell death,30 and countering TNF-α improves both symptoms and pathology.31,32 β-Amyloid aggregation in mouse hippocampus and cortex has also been induced by inflammation.33

In AD, abnormal TDP-43 staining is seen in up to 34% of cases.34 In most cases of comorbid AD/TDP, TDP inclusions are restricted to the medial temporal lobe, but a minority of cases shows a more widespread deposition pattern consistent with FTLD-TDP type A, the same pattern associated with GRN cases.35 The molecular links between TDP-43 and AD pathologies are not known. One study found elevated TDP-43 levels in an AD mouse model that correlated with Aβ oligomers; decreasing Aβ42 levels normalized TDP-43 in these mice.36 Whether this relationship could be bidirectional and TDP-43 levels may contribute to Aβ deposition as well is a topic for further investigation.

The present cases add support to the association between GRN and AD. As pathology from more cases becomes available, the strength and frequency of this association will be clarified.

Back to top
Article Information

Correspondence: David C. Perry, MD, University of California, San Francisco (UCSF) Memory and Aging Center, MC: 1207, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158 (dperry@memory.ucsf.edu).

Accepted for Publication: August 17, 2012.

Published Online: April 22, 2013. doi:10.1001/2013.jamaneurol.393

Author Contributions:Study concept and design: Perry, Lehmann, Seeley, Miller, Rosen, and Rabinovici. Acquisition of data: Perry, Karydas, Lee, Coppola, Grinberg, Seeley, Rosen, and Rabinovici. Analysis and interpretation of data: Perry, Lehmann, Yokoyama, Lee, Coppola, Grinberg, Geschwind, Seeley, Rosen, and Rabinovici. Drafting of the manuscript: Perry, Lehmann, and Rabinovici. Critical revision of the manuscript for important intellectual content: Lehmann, Yokoyama, Karydas, Lee, Coppola, Grinberg, Geschwind, Seeley, Miller, Rosen, and Rabinovici. Statistical analysis: Lehmann and Coppola. Obtained funding: Seeley, Rosen, and Rabinovici. Administrative, technical, and material support: Lehmann, Yokoyama, Lee, Grinberg, Seeley, and Rosen. Study supervision: Geschwind, Seeley, Miller, Rosen, and Rabinovici.

Conflict of Interest Disclosures: Dr Perry's work is funded by grant T32 AG23481 from the National Institutes of Health's National Institute on Aging. Dr Lehmann's work is funded by Alzheimer's Research UK. Dr Yokoyama's work is funded by a diversity supplement through grant P50 AG03006 from the National Institutes of Health's National Institute on Aging (principal investigator, Dr Miller). Dr Coppola's work is funded by R01 AG026938 and RC1 AG035610 from the National Institutes of Health's National Institute on Aging. Dr Grinberg's work is supported by the John Douglas French Alzheimer's Foundation and grants P50 AG023501-06 and 1R01AG040311-01 from the National Institutes of Health. Dr Rosen's work is supported by R01AG032306 and R01AG030688 from the National Institutes of Health's National Institute on Aging. Dr. Geschwind has received institutional support from Alzheimer's Disease Research Center of California (ARCC) grants 03-7527 and R01 AG026938. Dr Seeley's work is funded by grant P50 AG1657303 from the National Institutes of Health, the John Douglas French Alzheimer's Disease Foundation, the Consortium for Frontotemporal Dementia Research, the James S. McDonnell Foundation, and the Larry Hillblom Foundation. Dr Seeley has received support for travel by the Alzheimer's Association; has received payment for lectures by the Alzheimer's Association, the American Academy of Neurology, and Novartis Korea; and has served on advisory boards for Bristol Myers-Squibb. Dr Miller serves as board member on the John Douglas French Alzheimer's Foundation and Larry L. Hillblom Foundation; and he serves as a consultant for TauRx Ltd, Allon Therapeutics, the Tau Consortium, the Consortium for Frontotemporal Research, and the Siemens Molecular Imaging Biomarker Research Alzheimer's Advisory Group. Dr Miller has received institutional support from Novartis, and his work is funded by grants P50AG023501, P01AG019724, and P50 AG1657303 from the National Institutes of Health, and the state of California. Dr Rabinovici's work is funded by grant K23-AG031861 from the National Institutes of Health's National Institute on Aging.

Funding/Support: Funding support for this study came from the Consortium for Frontotemporal Research, the John Douglas French Alzheimer's Foundation, the Larry Hillblom Foundation, and the James S. McDonnell Foundation, as well as grants P50AG023501, P01AG019724, P50AG1657303, NIA K23-AG031861, R01AG040311, R01 AG026938, RC1 AG035620, T32AG23481, and R01AG032306 from the National Institutes of Health.

REFERENCES
1.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state:” a practical method for grading the cognitive state of patients for the clinician.  J Psychiatr Res. 1975;12(3):189-198PubMedArticle
2.
Ashburner J, Friston KJ. Voxel-based morphometry: the methods.  Neuroimage. 2000;11(6, pt 1):805-821PubMedArticle
3.
Ashburner J. A fast diffeomorphic image registration algorithm.  Neuroimage. 2007;38(1):95-113PubMedArticle
4.
Le Ber I, Camuzat A, Hannequin D,  et al; French Research Network on FTD/FTD-MND.  Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study.  Brain. 2008;131(pt 3):732-746PubMedArticle
5.
Gass J, Cannon A, Mackenzie IR,  et al.  Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.  Hum Mol Genet. 2006;15(20):2988-3001PubMedArticle
6.
Baker M, Mackenzie IR, Pickering-Brown SM,  et al.  Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.  Nature. 2006;442(7105):916-919PubMedArticle
7.
Cruts M, Gijselinck I, van der Zee J,  et al. 924 . Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21.  Nature. 2006;442(7105):920PubMedArticle
8.
The National Institute on Aging; Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease.  Neurobiol Aging. 1997;18(4):(suppl)  S1-S2PubMedArticle
9.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes.  Acta Neuropathol. 1991;82(4):239-259PubMedArticle
10.
Mackenzie IR, Neumann M, Baborie A,  et al.  A harmonized classification system for FTLD-TDP pathology.  Acta Neuropathol. 2011;122(1):111-113PubMedArticle
11.
Mesulam M, Wicklund A, Johnson N,  et al.  Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia.  Ann Neurol. 2008;63(6):709-719PubMedArticle
12.
Rademakers R, Baker M, Gass J,  et al.  Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative.  Lancet Neurol. 2007;6(10):857-868PubMedArticle
13.
Josephs KA, Ahmed Z, Katsuse O,  et al.  Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations.  J Neuropathol Exp Neurol. 2007;66(2):142-151PubMedArticle
14.
Brouwers N, Sleegers K, Engelborghs S,  et al.  Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease.  Neurology. 2008;71(9):656-664PubMedArticle
15.
Fenoglio C, Galimberti D, Cortini F,  et al.  Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease.  J Alzheimers Dis. 2009;18(3):603-612PubMed
16.
Lee MJ, Chen TF, Cheng TW, Chiu MJ. rs5848 variant of progranulin gene is a risk of Alzheimer's disease in the Taiwanese population.  Neurodegener Dis. 2011;8(4):216-220PubMedArticle
17.
Viswanathan J, Mäkinen P, Helisalmi S, Haapasalo A, Soininen H, Hiltunen M. An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population.  Am J Med Genet B Neuropsychiatr Genet. 2009;150B(5):747-750PubMedArticle
18.
Bruni AC, Momeni P, Bernardi L,  et al.  Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation.  Neurology. 2007;69(2):140-147PubMedArticle
19.
Morris JC, Roe CM, Xiong C,  et al.  APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.  Ann Neurol. 2010;67(1):122-131PubMedArticle
20.
Ward ME, Miller BL. Potential mechanisms of progranulin-deficient FTLD.  J Mol Neurosci. 2011;45(3):574-582PubMedArticle
21.
Bossù P, Salani F, Alberici A,  et al.  Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients.  J Neuroinflammation. 2011;8:65PubMedArticle
22.
Yin F, Banerjee R, Thomas B,  et al.  Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice.  J Exp Med. 2010;207(1):117-128PubMedArticle
23.
Tang W, Lu Y, Tian QY,  et al.  The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice.  Science. 2011;332(6028):478-484PubMedArticle
24.
Tan ZS, Beiser AS, Vasan RS,  et al.  Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.  Neurology. 2007;68(22):1902-1908PubMedArticle
25.
Hayes A, Thaker U, Iwatsubo T, Pickering-Brown SM, Mann DM. Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer's disease.  Neurosci Lett. 2002;331(3):171-174PubMedArticle
26.
Cagnin A, Brooks DJ, Kennedy AM,  et al.  In-vivo measurement of activated microglia in dementia.  Lancet. 2001;358(9280):461-467PubMedArticle
27.
Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice.  J Neurosci. 2008;28(33):8354-8360PubMedArticle
28.
Holmes C, Cunningham C, Zotova E,  et al.  Systemic inflammation and disease progression in Alzheimer disease.  Neurology. 2009;73(10):768-774PubMedArticle
29.
Yamamoto M, Kiyota T, Horiba M,  et al.  Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.  Am J Pathol. 2007;170(2):680-692PubMedArticle
30.
Janelsins MC, Mastrangelo MA, Park KM,  et al.  Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice.  Am J Pathol. 2008;173(6):1768-1782PubMedArticle
31.
He P, Zhong Z, Lindholm K,  et al.  Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice.  J Cell Biol. 2007;178(5):829-841PubMedArticle
32.
Shi JQ, Shen W, Chen J,  et al.  Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains.  Brain Res. 2011;1368:239-247PubMedArticle
33.
Lee JW, Lee YK, Yuk DY,  et al.  Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation.  J Neuroinflammation. 2008;5:37PubMedArticle
34.
Josephs KA, Whitwell JL, Knopman DS,  et al.  Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype.  Neurology. 2008;70(19, pt 2):1850-1857PubMed
35.
Uryu K, Nakashima-Yasuda H, Forman MS,  et al.  Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.  J Neuropathol Exp Neurol. 2008;67(6):555-564PubMedArticle
36.
Caccamo A, Magrí A, Oddo S. Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation.  Mol Neurodegener. 2010;5:51PubMedArticle
×